XRTX Stock Overview
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XORTX Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.95 |
| 52 Week High | CA$9.99 |
| 52 Week Low | CA$2.65 |
| Beta | -0.15 |
| 1 Month Change | -24.04% |
| 3 Month Change | 26.60% |
| 1 Year Change | -48.37% |
| 3 Year Change | -78.01% |
| 5 Year Change | -80.32% |
| Change since IPO | -92.52% |
Recent News & Updates
Recent updates
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation
Aug 23
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business
Apr 01We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow
Dec 16Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth
Sep 01Shareholder Returns
| XRTX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -8.1% | -3.9% | 1.2% |
| 1Y | -48.4% | 53.0% | 6.1% |
Return vs Industry: XRTX underperformed the Canadian Pharmaceuticals industry which returned 53% over the past year.
Return vs Market: XRTX underperformed the Canadian Market which returned 6.1% over the past year.
Price Volatility
| XRTX volatility | |
|---|---|
| XRTX Average Weekly Movement | 22.0% |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: XRTX's share price has been volatile over the past 3 months.
Volatility Over Time: XRTX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Allen Davidoff | www.xortx.com |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
XORTX Therapeutics Inc. Fundamentals Summary
| XRTX fundamental statistics | |
|---|---|
| Market cap | CA$11.45m |
| Earnings (TTM) | -CA$2.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs XRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.16m |
| Earnings | -US$2.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XRTX perform over the long term?
See historical performance and comparison